vacess
4 known investors
Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection. The platform targets patients seeking more convenient, pain-free administration of next-generation therapeutics.
Founders & leadership
RS
Rachel ShaCEO
Investors · 4
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Science Foundation | Phase I | 2020 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Science Foundation | Phase II | 2016 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $223.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $210.1K |
| National Science Foundation | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does vacess do?
- Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection. The platform targets patients seeking more convenient, pain-free administration of next-generation therapeutics.
- Who are vacess's investors?
- vacess's investors include Mission Biocapital, Norwich Ventures, Ulu Ventures, The Engine Ventures.